Evaluation of the clinical efficacy of trazoldone extended-release tablets in depressed patients with anxiety

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400094880

Enrollment

Unknown

Registered

2024-12-30

Start date

2025-01-01

Completion date

Unknown

Last updated

2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression with anxiety

Interventions

Experimental group:Tezodone extended release tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Meet the diagnostic criteria for depression disorders in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5); 17-item Hamilton Depression Scale (HAMD) score> 14, Hamilton Anxiety Scale (HAMA) score> 14; 2.Adult patients aged 18 years and older; 3.The patient voluntarily participated and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients with other mental disorders meeting the DSM-5 diagnostic criteria; 2.Patients with severe chronic somatic diseases and drug restrictions; 3.Excluding patients receiving antidepressants within 2 months; 4.Serious suicidal tendencies, unable to complete the project; 5.Excluding patients during pregnancy and lactation; 6.Abandve treatment or switch to other treatment.

Design outcomes

Primary

Measure	Time frame
The Hamilton Anxiety Scale (HAMA);The Hamilton Depression Scale (HAMD);	—

Secondary

Measure	Time frame
Automatic Thoughts Questionnaire;Beck Scale for Suicide Ideation;Global Assessment of Functioning (GAF);	—

Countries

China

Contacts

Public ContactHaisheng Zhang

Hangzhou First People's Hospital

zhanghaisheng3065@126.com+86 13735878181

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026